CTX Response to Risedronate Therapy

Clinical Significance and Measurement Considerations

• The American Society of Clinical Oncology (ASCO) guidelines state that biochemical markers, such as CTX, are not suggested for routine care and their value to guide treatment adjustments has not yet been shown 1, 2, 3
• CTX measurement has significant biological variability (15-40%) and is affected by time of day, fasting status, and renal function 1, 2, 3

Treatment Efficacy and Monitoring

• The utility of monitoring markers, such as CTX, to adjust bisphosphonate therapy remains unproven in clinical trials 1, 2